Canaccord Genuity Maintains Buy on Aclaris Therapeutics, Lowers Price Target to $12
Canaccord Genuity analyst Edward Nash maintains Aclaris Therapeutics (NASDAQ:ACRS) with a Buy and lowers the price target from $13 to $12.
Follow the latest Aclaris Therapeutics, Inc. (ACRS) news and market headlines alongside the live ACRS price. Stay informed on what's moving ACRS.

Canaccord Genuity analyst Edward Nash maintains Aclaris Therapeutics (NASDAQ:ACRS) with a Buy and lowers the price target from $13 to $12.
Analysts downgraded SWK, SHLS, TSN, IDA and ACRS, with mixed price-target changes; ACRS saw the steepest cut, from $8 to $3.
Wedbush analyst Martin Fan downgrades Aclaris Therapeutics (NASDAQ:ACRS) from Outperform to Neutral and lowers the price target from $8 to $3.
U.S. stock futures fell as Red Cat plunged 25.8% after weak Q3 results and withdrawing FY26 guidance; several stocks also declined premarket.
Aclaris Therapeutics misses Phase 2 bosakitug endpoints but launches its Phase 2b modzatinib trial for moderate-to-severe lichen planus.
U.S. stock futures fell as Aclaris plunged 21% after its dermatitis trial failed; Summit and other stocks also dropped in premarket trading.
Take-Two rose 4% ahead of GTA VI’s Nov. 19 release on strong presales. GreenPower led gainers, while Datavault AI plunged 43%.
- Dual Inhibition of ITK and JAK3 Provides Potential for Modzatinib to be the First Mechanistically Complete Oral Therapy for Lichen Planus, an Unaddressed Inflammatory Disease with No Approved Therapeutic Options --
- The ADMIRATION Trial Did Not Achieve its Primary Endpoint of Percent Change in Eczema Area and Severity Index (EASI) Score from Baseline at Week 24 -- Aclaris Remains Focused on Prioritizing the Development of its
News and data on this page is provided by our partnered third-party news and market data provider, with the original publisher credited on each article. All third-party content reflects the views of the original publisher and does not represent the views of MEXC. Price and market data shown on this page are provided by third-party data providers and may be delayed. MEXC offers trading products related to ACRS, including RealStocks and Stock Futures.
The content on this page is provided for informational purposes only and does not constitute investment, financial, or trading advice. MEXC makes no guarantees regarding the accuracy, completeness, or timeliness of any news or market data shown. Trading U.S. stocks and related products involves significant risk, and prices can move sharply in a short period. Past performance does not guarantee future results. Please conduct your own research and assess your financial situation and risk tolerance before making any investment decisions. MEXC is not liable for any losses arising from the use of this information.